Self-immolative nanocapsules precisely regulate depressive neuronal microenvironment for synergistic antidepression...

Area of Science:

• Neuroscience
• Nanotechnology
• Pharmacology

Background:

• Pharmacotherapy is the primary depression treatment but faces limitations like delayed effects and side effects.
• Nanotechnology offers potential to improve drug delivery across the blood-brain barrier (BBB) for faster therapeutic action.
• Existing commercial drugs have inherent limitations hindering effective brain-targeted delivery.

Purpose of the Study:

• To engineer a nanocapsule system for delivering serotonin (5-hydroxytryptamine, 5-HT) and catalase (CAT) to the brain.
• To achieve synergistic antidepressant effects by combining 5-HT and CAT delivery.
• To overcome limitations of current depression pharmacotherapy using nanotechnology.

Main Methods:

• Fabrication of nanocapsules via 5-HT polymerization with simultaneous CAT loading.
• Surface modification of nanocapsules using human serum albumin and rabies virus glycoprotein for BBB penetration.
• Utilizing virus-inspired surface strategies for enhanced brain targeting.

Main Results:

• Engineered nanocapsules demonstrated significant blood-brain barrier (BBB) penetration.
• Mildly acidic brain conditions triggered the release of 5-HT, positively regulating mood.
• Delivered catalase (CAT) alleviated neuroinflammation and enhanced 5-HT's therapeutic efficacy.

Conclusions:

• The developed nanoantidepressants show potential for synergistic depression therapy.
• Results encourage rational design of nanodrugs for mental health applications.
• Nanotechnology holds significant promise for treating neurological and psychiatric disorders.